Evidence map›Paper›PMID 30063202›Full record

ArticleMicrobial genomics2018

Genomic surveillance of Neisseria gonorrhoeae to investigate the distribution and evolution of antimicrobial-resistance determinants and lineages.

Koji Yahara, Shu-Ichi Nakayama, Ken Shimuta, Ken-Ichi Lee, Masatomo Morita, Takuya Kawahata, Toshiro Kuroki, Yuko Watanabe, Hitomi Ohya, Mitsuru Yasuda and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Microbial genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. A Multiplex Molecular Assay for Detection of SixAntimicrobial agents and chemotherapy · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Typing ofAntimicrobial agents and chemotherapy · 2021
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Koji Yahara1​Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Shu-Ichi Nakayama2​Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
Ken Shimuta2​Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
Ken-Ichi Lee2​Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
Masatomo Morita2​Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
Takuya Kawahata3​Virology Section, Division of Microbiology, Osaka Institute of Public Health, Osaka, Japan.
Toshiro Kuroki4​Department of Microbiology, Kanagawa Prefectural Institute of Public Health, Kanagawa, Japan.
Yuko Watanabe4​Department of Microbiology, Kanagawa Prefectural Institute of Public Health, Kanagawa, Japan.
Hitomi Ohya4​Department of Microbiology, Kanagawa Prefectural Institute of Public Health, Kanagawa, Japan.
Mitsuru Yasuda5​Department of Urology, Graduate School of Medicine, Gifu University, Gifu, Japan.
Takashi Deguchi5​Department of Urology, Graduate School of Medicine, Gifu University, Gifu, Japan.
Xavier Didelot6​Department of Infectious Disease Epidemiology, Imperial College, London, UK.
Makoto Ohnishi2​Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan.
National Institute of Infectious Diseases · JPKanagawa Prefectural Institute of Public Health · JPGifu University · JPImperial College London · GBOsaka Prefectural Institute of Public Health · JP

Funding

Medical Research Council MR/R015600/1
6 · The paper itself

Abstract

The first extensively drug resistant (XDR) Neisseria gonorrhoeae strain with high resistance to the extended-spectrum cephalosporin ceftriaxone was identified in 2009 in Japan, but no other strain with this antimicrobial-resistance profile has been reported since. However, surveillance to date has been based on phenotypic methods and sequence typing, not genome sequencing. Therefore, little is known about the local population structure at the genomic level, and how resistance determinants and lineages are distributed and evolve. We analysed the whole-genome sequence data and the antimicrobial-susceptibility testing results of 204 strains sampled in a region where the first XDR ceftriaxone-resistant N. gonorrhoeae was isolated, complemented with 67 additional genomes from other time frames and locations within Japan. Strains resistant to ceftriaxone were not found, but we discovered a sequence type (ST)7363 sub-lineage susceptible to ceftriaxone and cefixime in which the mosaic penA allele responsible for reduced susceptibility had reverted to a susceptible allele by recombination. Approximately 85 % of isolates showed resistance to fluoroquinolones (ciprofloxacin) explained by linked amino acid substitutions at positions 91 and 95 of GyrA with 99 % sensitivity and 100 % specificity. Approximately 10 % showed resistance to macrolides (azithromycin), for which genetic determinants are less clear. Furthermore, we revealed different evolutionary paths of the two major lineages: single acquisition of penA X in the ST7363-associated lineage, followed by multiple independent acquisitions of the penA X and XXXIV in the ST1901-associated lineage. Our study provides a detailed picture of the distribution of resistance determinants and disentangles the evolution of the two major lineages spreading worldwide.

Indexed as

Anti-Bacterial AgentsEvolution, MolecularGenome, BacterialDrug Resistance, Multiple, BacterialGonorrheaHumansJapanNeisseria gonorrhoeaeR FactorsAnti-Bacterial Agentsantimicrobial resistancecephalosporincoalescentfluoroquinolonegenomic epidemiologymacrolideNeisseria gonorrhoeaephylogenyrecombinationsurveillance

Identifiers

PMID30063202
PMCPMC6159555
OpenAlexW2886375474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.